



Present and Future of Antibiotic Treatment for Carbapenem-Resistant Enterobacteriaceae

Guest Editor:

Dr. Dafne Bongiorno

Department of Biomedical and
Biotechnological Sciences
(BIOMETEC), Medical Molecular
Microbiology and Antibiotic
Resistance Laboratory
(MMARLab), University of Catania,
Catania, Italy

Deadline for manuscript
submissions:

20 June 2024

Message from the Guest Editor

Carbapenem-resistant Enterobacteriaceae (CRE) infections have emerged as a major public health concern over the past few decades.

This Special Issue aims to shed light on the present and future of antibiotic treatment for CRE, focusing on the latest research advancements, clinical trials, and therapeutic interventions. By bringing together research from various disciplines, including microbiology, pharmacology, and clinical medicine, this collection of articles aims to provide a comprehensive overview of the current landscape and prospects in the fight against CRE.

We invite researchers, clinicians, and industry professionals to contribute their insights and findings to this Special Issue. We will delve into the mechanisms underlying carbapenem resistance in Enterobacteriaceae, explore novel therapeutic targets and approaches, and discuss the challenges and opportunities in developing new antibiotics.

In addition, Dr. Dalida Bivona from the Biomedical and Biotechnological Sciences Department, University of Catania, will be a co-worker to help care for this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)